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Abstract
Background: Phosphaturic mesenchymal tumors (PMTs) are rare neoplasms that are often associated with
tumor-induced osteomalacia (TIO) due to excessive serum levels of fibroblast growth factor 23 (FGF23). PMTs
share overlapping histologic features with other types of tumors; thus, accurate pathological diagnosis may be
challenging. We performed an immunohistochemical examination of FGF23 expression in PMTs and other
types of tumors, together with pertinent molecular analyses.
Methods: Seven PMTs (5 with TIO and 2 without TIO) and 46 other types of bone and soft tissue tumors
were retrieved, and immunohistochemistry was performed using a commercially available anti-FGF23 antibody.
In addition, FGF23 mRNA expression was detected by reverse transcription-polymerase chain reaction (RT-PCR),
using RNA extracted from formalin-fixed, paraffin-embedded tissues.
Results: Immunohistochemical analysis of FGF23 expression showed distinct, punctate staining in the cytoplasm in 5
PMTs with TIO, whereas FGF23 expression was negative in the 2 PMTs without TIO and the other 46 tumors. FGF23
mRNA expression was detected in all 4 PMTs examined, as well as in 1 chondromyxoid fibroma and 1 myxoid
liposarcoma. The real-time RT-PCR data showed that the relative expression levels of the FGF23 mRNA tended to be
higher in PMTs with TIO than in PMTs without TIO, or in the chondromyxoid fibroma specimen.
Conclusions: Our data suggested that the feasibility of immunohistochemical detection of FGF23 may depend on the
level of secreted FGF23 from tumor cells. Thus, immunohistochemistry for FGF23 is an useful diagnostic adjunct for
PMT, although its utility appears to be limited in cases without TIO.
Keywords: Phosphaturic mesenchymal tumor, Tumor-induced osteomalacia, Non-phosphaturic variant, Fibroblast
growth factor 23, Immunohistochemistry, Polymerase chain reaction
Background
Tumor-induced osteomalacia (TIO) was previously de-
scribed as involving various types of bone and soft tissue
tumors such as hemangiopericytoma (an obsolete term,
which is now referred to as solitary fibrous tumor),
chondroblastoma, and osteosarcoma [1–5]. Recent
findings have revealed that the majority of such cases
encompasses a single entity with distinctive histological
features, and this specific group of lesions has been
designated as phosphaturic mesenchymal tumor (PMT)
[1–3]. The formation of TIO in PMTs is thought to re-
sult from an excessive serum level of tumor-derived
fibroblast growth factor 23 (FGF23) [3–5], which is an
osteocyte-derived phosphaturic hormone that inhibits
renal phosphate reabsorption and the production of
1,25(OH)2 vitamin D by reducing the activity of renal
1α-hydroxylase [6–8]. However, rare PMTs likely express
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other phosphaturic hormones (e.g., frizzled-related protein
4 and matrix extracellular phosphoglycoprotein) [9–11].
The minor fraction of PMTs that lack clinical evidence of
TIO is referred to as the non-phosphaturic variant [3].
In 2009, Bahrami et al. [12] reported the diagnostic
utility of detecting FGF23 transcripts in PMTs by the re-
verse transcription-polymerase chain reaction (RT-PCR)
using formalin-fixed, paraffin-embedded (FFPE) tumor
tissues. Although RT-PCR testing is highly sensitive,
FGF23 mRNA is considered to be structurally normal
and could also be detected in non-PMT tumors, includ-
ing aneurysmal bone cysts and chondromyxoid fibromas
[12–14]. A more reliable diagnostic adjunct for routine
pathology testing is required.
Here, we performed immunohistochemical staining for
FGF23 expression in PMTs, with or without TIO, and
other types of bone and soft tissue tumors using a com-
mercially available anti-FGF23 antibody together with
real-time RT-PCR, This approach allowed us to address
differences in FGF23 expression between PMTs, with
and without TIO.
Table 1 Immunohistochemical results of FGF23
Diagnosis Positive








Clear cell sarcoma 0/2
Myxoid liposarcoma 0/1
Solitary fibrous tumor 0/4
Giant cell tumor of bone 0/4
Giant cell tumor of tendon sheath 0/6
Aneurysmal bone cyst 0/4




Site Diagnosis TIO IHC RT-PCR
FGF23a/b/c
1 35/F Popliteal region Phosphaturic mesenchymal tumor + + +/+/+
2 59/F Groin Phosphaturic mesenchymal tumor + + +/+/+
3 59/F Nasal cavity Phosphaturic mesenchymal tumor + + NA
4 61/M Lower leg Phosphaturic mesenchymal tumor + + NA
5 46/F Nasal cavity Phosphaturic mesenchymal tumor + + NA
6 38/F Foot Phosphaturic mesenchymal tumor - - +/+/+
7 43/M Radius Phosphaturic mesenchymal tumor - - +/+/+
8 57/M Distal phalanx Chondromyxoid fibroma - NA
9 30/M Fibula Chondromyxoid fibroma - +/−/+
10 23/M Patella Chondroblastoma - −/−/-
11 15/M Humerus Chondroblastoma - −/−/-
12 26/M Calcaneus Chondroblastoma - −/−/-
13 57/M Tibia Chondroblastoma - −/−/-
14 74/F Middle finger Giant cell tumor of tendon sheath - −/−/-
15 66/M Index finger Giant cell tumor of tendon sheath - −/−/-
16 51/F Wrist Giant cell tumor of tendon sheath - −/−/-
17 62/F Femur Giant cell tumor of bone - −/−/-
18 39/M Femur Giant cell tumor of bone - −/−/-
19 70/F Femur Aneurysmal bone cyst - −/−/-
20 74/F Femur Aneurysmal bone cyst - −/−/-
21 71/F Vertebra Aneurysmal bone cyst - −/−/-
22 20/M Thigh Extraskeletal mesenchymal chondrosarcoma - −/−/-
23 65/F Lower leg Myxoid liposarcoma - −/+/−
IHC immunohistochemistry, NA not available, RT-PCR reverse transcription-polymerase chain reaction, TIO tumor-induced osteomalacia
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Methods
Archived specimens from 7 PMTs (5 with TIO and 2 with-
out TIO) and 46 other bone and soft tissue tumors (6
chondromyxoid fibromas, 4 chondroblastomas, 4 chondro-
sarcomas, 1 extraskeletal mesenchymal chondrosarcoma, 5
osteosarcomas, 3 synovial sarcomas, 2 angiosarcomas, 2
clear cell sarcomas, 1 myxoid liposarcoma, 4 solitary
fibrous tumors, 4 giant cell tumors of the bone, 6 giant cell
tumors of the tendon sheath, and 4 aneurysmal bone cysts)
were obtained from our institution. PMT diagnosis was
made based on clinical information and morphological
findings, including dirty or smudgy calcification, as deter-
mined by two pathologists (M.H. & A.M.). For immunohis-
tochemical examinations, histological sections of FFPE
tumor specimens were incubated with an anti-FGF23
monoclonal antibody (FG322-3, 1:500 dilution; Adipogen,
San Diego, CA, USA) at room temperature for 24 h after
epitope retrieval in ethylenediaminetetraacetic acid buffer
(pH 8.0) using a pressure cooker, followed by treatment
with 3 % hydrogen peroxide for 10 min. Immunostaining
was accomplished by incubation with a labeled polymeric
secondary antibody (Histofine Simple stain MAX PO,
Nichirei, Tokyo, Japan). Diaminobenzidine solution was
used for visualization, followed by nuclear counterstaining
with hematoxylin. As described by Nelson et al. [15] and
Houang et al. [16], distinct “dot-like” cytoplasmic staining
of FGF23 was considered to represent a positive result,
whereas diffuse cytoplasmic and nuclear staining were
interpreted as non-specific findings.
For molecular detection of the FGF23 gene transcript,
total RNA was extracted from FFPE tissues using the
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and re-
verse transcribed into cDNA. RT-PCR-based analysis of
the FGF23 transcripts was performed using 3 different
sets of primers designed by Bahrami et al. [12]. The
transcripts of reference genes (phosphoglycerate kinase
and porphobilinogen deaminase) were amplified along
with FGF23 as quality controls. Quantitative analysis of
FGF23 mRNA expression was performed by real-time
RT-PCR analysis using a TaqMan Gene Expression
Assay (Applied Biosystems, Foster City, CA, USA), ac-
cording to the manufacturer’s instructions. Briefly, 20-μl
PCR reaction mixtures containing 1× TaqMan Gene Ex-
pression Master Mix, 1× TaqMan Gene Expression
Assay, and the reverse transcription products were incu-
bated at 95 °C for 10 min, followed by 40 cycles at 95 °C
for 15 s and at 60 °C for 1 min. Standard curves were
generated to quantitate the data. FGF23 mRNA expres-
sion levels were normalized to that of the glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene, as an
endogenous control.
The study design was approved by an ethics review board
of the University of Occupational and Environmental
Health (H25-169).
Fig. 2 PMT without TIO. a: The tumor was characterized by the proliferation of bland spindle cells, with grungy calcification. b: Immunohistochemical
staining showed that the tumor cells were negative for FG322-3
Fig. 1 PMT with TIO. a: The tumor was characterized by the proliferation of bland spindle or oval cells, with grungy calcification. b: By immunohistochemical
staining, FG322-3 expression showed a distinct, dot-like staining pattern (arrows)
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Results and discussion
The results of our immunohistochemistry analysis of
FGF23 expression in the tumor specimens examined are
summarized in Table 1. Five of 7 (71.4 %) PMTs were
positive for FG322-3, and showed a distinct, punctate
intracytoplasmic and perinuclear staining pattern in 5–
20 % of the tumor cells (Fig. 1). Most positive cells were
oval or spindle-shaped and tended to reside in densely
populated cellular areas, rather than hypocellular calcified
areas. All 5 of the FG322-3-positive PMTs had TIO. In
contrast, no FG322-3-positive cells were observed among
the 2 PMTs without TIO (Fig. 2) or the 46 non-PMT tu-
mors, although non-specific nuclear and/or diffuse cyto-
plasmic staining was noted in 9 cases (Figs. 3 and 4).
Results of the cases evaluated by a RT-PCR analysis
are summarized in Table 2. During RT-PCR analysis,
FGF23 gene transcripts were identified in all 4 PMTs ex-
amined, 2 of which were associated with TIO (Fig. 5).
Only 2 of the 3 FGF23 transcripts examined were de-
tected in a chondromyxoid fibroma, and 1 of the 3 stud-
ied transcripts was identified in a myxoid liposarcoma
(Fig. 5). No FGF23 transcript was amplified in the other
tumors examined. Analysis of our real-time RT-PCR
data showed that the relative expression levels of the
FGF23 gene transcripts tended to be higher in PMTs
with TIO than those without TIO, or in chondromyxoid
fibroma samples (Fig. 6). The FGF23 gene transcript was
not amplified in the other tumor specimens examined,
including the myxoid liposarcoma specimen (Fig. 6).
PMT is a rare neoplasm of soft tissues and bones that
arises predominantly in middle-aged adults and generally
has a benign clinical course [3–5]. The characteristic mor-
phological features of PMTs include bland spindle cell
cytomorphology, a low mitotic activity, grungy or floccu-
lent calcification, and a myxoid or myxochondroid stroma
[3–5]. Osteoclast-like giant cells, microcystic changes, an
osteoid matrix, hemangiopericytomatous blood vessels,
and a mature adipose-tissue component may be present
in some cases [3–5]. However, some PMTs may contain
areas of high-grade sarcoma resembling undifferentiated
pleomorphic sarcoma or fibrosarcoma and often behave
in an aggressive manner. In addition, histologically benign
PMTs may also metastasize [17–20]. An accurate diagno-
sis of PMT is often difficult due to histological heterogen-
eity, and differential diagnoses include many other types
of tumors with some similar morphologic features, such
as chondromyxoid fibroma, chondroblastoma, aneurysmal
bone cyst, and osteosarcoma.
In this study, we found that the immunohistochemical
expression of FGF23 was highly specific for PMTs with
TIO (100 %). The sensitivity was 71.4 % in our overall
series of PMTs tested, and 100 % in the phosphaturic
variant. Although the number of examined tumor sam-
ples was small, our data suggest that FGF23 is a useful
immunohistochemical marker for PMT with TIO. It is
important to note that only the punctate staining pattern
was considered to be positive, similar to previous studies
using other anti-FGF23 antibody clones [15, 16]. Diffuse
cytoplasmic and nuclear staining are occasionally en-
countered in non-PMT tumors or normal tissues at in-
appropriately high antibody concentrations, whereas
Fig. 4 Non-specific FG322-3 immunostaining observed using a high antibody concentration. a: Diffuse cytoplasmic staining in a chondromyxoid
fibroma. b: Nuclear staining in an aneurysmal bone cyst
Fig. 3 Chondromyxoid fibroma. Inset: Weak nuclear staining of FG322-3
was noted in a small proportion of the tumor cells (arrow)
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such staining patterns are inconspicuous or absent at low
concentrations. In addition, no FGF23 gene transcript was
detected by RT-PCR analysis in non-PMT tumors display-
ing these staining patterns. Thus, the perinuclear, dot-like
staining pattern is reliable phenotypic characteristic of
FGF23 expression. Similar perinuclear staining patterns of
other markers have been observed during the immunohis-
tochemical analyses of several other tumor types, including
Merkel cell carcinoma (cytokeratin 20) [21], desmoplastic
small round cell tumors (desmin) [22], and Hodgkin’s
lymphoma (CD30) [23]. In these tumors, the unique stain-
ing patterns are considered to result from clumping of
intermediate filaments [21, 22], or the accumulation of
protein precursors in the Golgi area. [23]. In PMTs, the
punctate staining pattern may result from an accumulation
of highly expressed FGF23 precursor molecules in the
Golgi apparatus, although further investigations are needed
to address the mechanisms underlying the unique intracel-
lular localization pattern of FGF23.
Immunohistochemical examination of FGF23 expres-
sion in tumors using a commercially available antibody
has been limited thus far [16]. Folpe et al. [3] reported
that not only PMTs with TIO, but also PMTs without
TIO and some other tumors were immunohistochemi-
cally positive for FGF23, using a polyclonal antibody.
They scored diffuse cytoplasmic staining as positive
and concluded that this staining was not specific.
Houang et al. [16] reported that 14 PMTs (all with
TIO) and 2 of 40 non-PMT tumors in their series were
positive for FGF23 using a different commercially avail-
able antibody (polyclonal, 1:100 dilution; Immutopics
Inc., San Clemente, CA, USA). The cytoplasmic dot-like
expression pattern and the distribution of positive tumor
cells observed in their study appeared similar to our re-
sults. Although single cases of aneurysmal bone cyst and
Fig. 6 The relative expression levels of FGF23 in PMTs, as determined by real-time RT-PCR analysis. The expression level of FGF23 was higher in PMTs with
TIO (case Nos. 1 and 2) than in PMTs without TIO (case Nos. 6 and 7) or chondromyxoid fibroma (case No. 9). The FGF23 gene transcript was not identified
in the other tumors examined, including myxoid liposarcoma (case No. 23). Expression levels were normalized to GAPDH as an internal control
Fig. 5 RT-PCR analysis of FGF23 transcripts. All 3 FGF23 transcripts
(23a, 140 bp; 23b, 125 bp; 23c, 175 bp) were amplified in PMTs (with
TIO: case Nos. 1, 2, without TIO: case Nos. 6, 7), whereas only 2 or 1
of the 3 transcripts were detected in the chondromyxoid fibroma
sample (case No. 9) or the myxoid liposarcoma sample (case No. 23),
respectively. M, 100-bp DNA ladder; N, negative control; PGK,
phosphoglycerokinase; PBGD, porphobilinogen deaminase; CMF,
chondromyxoid fibroma
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osteosarcoma were also positive for FGF23 in their study,
it is difficult to conclude that these tumors are unequivo-
cally different from PMTs without TIO, due to their po-
tential morphological overlap.
By RT-PCR analysis, FGF23 gene transcripts were iden-
tified not only in the 4 PMTs examined, but also in 1
chondromyxoid fibroma and 1 myxoid liposarcoma. How-
ever, no FGF23 gene transcripts were detected in the myx-
oid liposarcoma sample by real-time RT-PCR. The
difference of the primer sequences used in either analysis
might contribute to these incongruous results. Because
only 1 of the 3 targeted transcripts was detected in the
myxoid liposarcoma sample by RT-PCR, a potentially
non-functioning splicing variant of FGF23 might have
been amplified. Semi-quantitative analysis of the FGF23
gene transcript by real-time RT-PCR showed that the rela-
tive expression level tended to be higher in PMTs with
TIO than in PMTs without TIO. Tumor cells in the non-
phosphaturic variant of PMT may produce FGF23 at a
low level. The immunohistochemical expression of
FGF23, as well as the clinical manifestation of TIO, may
be dependent on the level of secreted FGF23 by tumor
cells. The expression level of the FGF23 gene transcript in
the chondromyxoid fibroma was also lower than observed
in PMTs with TIO; however, it was comparable to PMTs
without TIO. These results raise a concern as to whether
chondromyxoid fibroma can be completely distinguished
from the non-phosphaturic variant of PMT, because it is
occasionally challenging to differentiate chondromyxoid
fibroma from PMT [24, 25]. Chondromyxoid fibromas
typically show a distinct lobular architecture and rarely
contain dilated blood vessels. However, the clinical infor-
mation of TIO may be overlooked, and the histopatho-
logical distinction of these tumors may be somewhat
arbitrary. Recently, the FN1-FGFR1 fusion gene was iden-
tified in PMTs using next-generation RNA sequencing
[26], and upregulation of metabotropic glutamate receptor
1 (GRM1) expression through gene fusion and promoter
swapping was detected in chondromyxoid fibroma [27].
These distinct molecular profiles may be helpful to differ-
entiate both entities or to diagnose the non-phosphaturic
variant of PMT.
Conclusions
The immunohistochemical expression of FGF23 in PMTs
may depend on the level of secreted FGF23 from tumor
cells. Thus, immunohistochemical staining for FGF23 may
serve as a diagnostic adjunct of PMTs, particularly those
with TIO, although further investigations using a greater
number of clinical specimens are necessary.
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